
Wednesday, March 06, 2019 8:27:34 PM

Liked By
Spread the love. Be the first to like this post!
Recent HUGE News
- FSD Pharma Appoints Former Ontario Minister of Health Doctor Eric Hoskins to Board of Directors • Business Wire • 05/25/2023 11:30:00 AM
- InvestmentPitch Media Video Discusses FSD Pharma’s Cost Award of $2.81 Million from Dr. Raza Bokhari in an Arbitration Settlement • GlobeNewswire Inc. • 05/16/2023 10:00:00 AM
- FSD Pharma Announces Receipt of Court Action and Update on Spin-Out and Distribution • Business Wire • 05/12/2023 09:00:00 PM
- FSD Pharma Awarded $2.81 Million in Cost Awards From Dr. Raza Bokhari • Business Wire • 05/11/2023 11:30:00 AM
- FSD Pharma Completes Dosing of First Cohort in Phase I Clinical Trial of Lucid-MS, a New Drug Candidate for the Treatment of Multiple Sclerosis: Safety Review Committee Recommends Commencing Dosing of Second Cohort • Business Wire • 05/10/2023 11:30:00 AM
- FSD Pharma to Present at Sidoti Virtual Investor Conference May 10-11 • Business Wire • 05/08/2023 12:50:00 PM
- FSD Pharma Achieves Milestone in Completion of Dosing of Sentinel Subjects in First-in-Human Clinical Trial of Lucid-MS (Lucid-21-302) for Multiple Sclerosis • Business Wire • 04/17/2023 01:00:00 PM
- FSD Pharma Announces Plan to Spin-Out Subsidiary as Distribution to Shareholders; Shareholder Meeting Scheduled for June 29, 2023 • Business Wire • 04/12/2023 12:30:00 PM
- FSD Pharma Announces Filing of Year-End 2022 Results • Business Wire • 04/01/2023 12:00:00 AM
- FSD Pharma Adds Former Celsius Holdings CEO Gerry David to Board of Advisors • Business Wire • 03/30/2023 12:30:00 PM
- FSD Pharma Announces Its Australian Entity Receives Approval to Proceed With Phase 1 Clinical Trial of Lucid-201, a Candidate for the Potential Treatment of Major Depressive Disorder • Business Wire • 03/22/2023 12:30:00 PM
- FSD Pharma (Symbol: HUGE) Renews Shareholder Intelligence Services to Investigate Possible Naked Short Selling and Appeals to The Regulators and Oversight Bodies to Look Into The Short Selling Activity Of Its Stock • Business Wire • 03/14/2023 12:30:00 PM
- InvestmentPitch Media Video Discusses FSD Pharma’s Addition of Kevin Harrington, Author, “Shark Tank” Original, and Infomercial Pioneer to its Advisory Board • GlobeNewswire Inc. • 03/01/2023 11:00:00 AM
- Original “Shark” and Iconic Entrepreneur Kevin Harrington Joins FSD Pharma Advisory Board • Business Wire • 02/28/2023 01:30:00 PM
- FSD Pharma Presenting Two Scientific Posters on Preclinical Toxicology and Efficacy Data of Lucid-21-302 (Lucid-MS) at Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) 2023 Forum • Business Wire • 02/21/2023 07:30:00 AM
- FSD Pharma Regains Compliance with NASDAQ Continued Listing Requirements • Business Wire • 02/15/2023 12:30:00 PM
- FSD Pharma Launches A New Research and Development Program Targeting Unmet Medical Needs for Alcohol Misuse • Business Wire • 02/14/2023 07:30:00 AM
- InvestmentPitch Media Video Discusses FSD Pharma’s Receipt of No Objection Letter from Health Canada for Clinical Trials for LUCID-21-302 for MS • GlobeNewswire Inc. • 02/09/2023 11:00:00 AM
- FSD Pharma Receives Regulatory Clearance for Its Proposed Phase-1 Clinical Trial of Lucid-21-302 (Lucid-MS), First-in-Class Multiple Sclerosis Drug Candidate • Business Wire • 02/07/2023 01:30:00 PM
- Recruiting Underway in FSD Pharma’s Phase 2 Trial of FSD-PEA (FSD201) for the Treatment of Chronic Pain Associated With Idiopathic MCAS (MCAD) • Business Wire • 01/30/2023 01:30:00 PM
- InvestmentPitch Media Video Discusses FSD Pharma’s Submission of its Clinical Trial Application for Planned Phase-1 Trial for Lucid-MS, a Candidate for Treatment of MS • GlobeNewswire Inc. • 01/19/2023 11:00:00 AM
- FSD Pharma submits its phase-1 Clinical Trial Application for Lucid-MS (Lucid-21-302) for first-in-human safety and tolerability investigation • Business Wire • 01/17/2023 01:30:00 PM
- FSD Pharma Announces Share Repurchase Program • Business Wire • 01/13/2023 01:30:00 PM
- FSD Pharma Inc Incorporates New Subsidiary to Capitalize on Drug Development Incentives in Australia • Business Wire • 01/09/2023 01:30:00 PM
- FSD Pharma to Attend 41st Annual J.P. Morgan Healthcare Conference 2023 • Business Wire • 01/06/2023 01:30:00 PM
Home Advantage: How Domestic REE Supply Is Supercharging North American Companies • UURAF • Jun 9, 2023 9:37 AM
Mass Megawatts Targets Profitable Fiscal Quarter Ending October 31 and Introduces New Tech for Potential Project Paybacks of Less Than Three Years on June 29 • MMMW • Jun 9, 2023 7:50 AM
Defiance Drills Widest Silver Intercept to Date in the Veta Grande • DNCVF • Jun 8, 2023 1:15 PM
Interactive Strength Inc. d/b/a FORME Reports First Quarter 2023 Results • TRNR • Jun 8, 2023 10:53 AM
Sadot LLC Achieves $9.9 Million Net Income Threshold, Triggers Nomination of Final Three Board Positions • GRIL • Jun 8, 2023 9:09 AM
MRES: Institute of Biomedical Research unveils artificial intelligence (AI) powered initiatives within its CBD product range, psilocybin research, and cardiometabolic health solutions • MRES • Jun 7, 2023 10:06 AM